ReviewBiology2021
Oncogenic Potential of the Dual-Function Protein MEX3A.
Review in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 22 citations in OpenAlex.
- Mex3a Stabilizes INHBB mRNA to Activate Smad Signaling and Promote Hepatocellular Carcinoma Metastasis.Annals of surgical oncology · 2026Article
- Comprehensive pan-cancer analysis of MEX3A in human tumors.Discover oncology · 2026Article
- Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma.Frontiers in oncology · 2026Article
- RNA-Binding Proteins: Modulators of Canonical Wnt Signaling Pathway.International journal of molecular sciences · 2025Review
- Role of MEX3A in tumorigenesis: Mechanisms, tumor‑specific effects and therapeutic implications (Review).International journal of molecular medicine · 2025Review
- Mex3a-dependent post-transcriptional silencing ensures olfactory receptor diversity and axon guidance specificity.Cell reports · 2025Article
- Correlation between prognostic markers and clinical parameters in hepatocellular carcinoma: Pathophysiological aspects to therapeutic targets.World journal of gastrointestinal oncology · 2025Article
- MEX3A is a diagnostic, independent prognostic biomarker and a promising therapeutic target in glioblastoma.Frontiers in oncology · 2025Article
- Nucleic acid-binding KH domain proteins influence a spectrum of biological pathways including as part of membrane-localized complexes.Journal of structural biology: X · 2024Article
- MEX3A promotes colorectal cancer migration, invasion and EMT via regulating the Wnt/β-catenin signaling pathway.Journal of cancer research and clinical oncology · 2024Article
- Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma.Nature communications · 2024Article
- Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma.Journal of translational medicine · 2024Article
- Establishment and Validation of a Four-stress Granule-related Gene Signature in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2024Article
- Mex3a promoter hypomethylation can be utilized to diagnose HBV-associated hepatocellular carcinoma: a randomized controlled trial.Frontiers in pharmacology · 2024Article
- MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way.Hepatology international · 2023Article
- The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.Breast cancer research and treatment · 2023Article
- MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis.Cancer research · 2023Article
- HPV and radiosensitivity of cervical cancer: a narrative review.Annals of translational medicine · 2022Review
- MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS.Cell death & disease · 2022Article
- RNA-binding protein MEX3A controls G1/S transition via regulating the RB/E2F pathway in clear cell renal cell carcinoma.Molecular therapy. Nucleic acids · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
MEX3A belongs to the MEX3 (Muscle EXcess) protein family consisting of four members (MEX3A-D) in humans. Characteristic for MEX3 proteins is their domain structure with 2 HNRNPK homology (KH) domains mediating RNA binding and a C-terminal really interesting new gene (RING) domain that harbors E3 ligase function. In agreement with their domain composition, MEX3 proteins were reported to modulate both RNA fate and protein ubiquitination. MEX3 paralogs exhibit an oncofetal expression pattern, they are severely downregulated postnatally, and re-expression is observed in various malignancies. Enforced expression of MEX3 proteins in various cancers correlates with poor prognosis, emphasizing their oncogenic potential. The latter is supported by MEX3A's impact on proliferation, self-renewal as well as migration of tumor cells in vitro and tumor growth in xenograft studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.